Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

2.89SEK
4:36am EST
Change (% chg)

-0.03kr (-1.03%)
Prev Close
2.92kr
Open
2.95kr
Day's High
2.97kr
Day's Low
2.85kr
Volume
195,818
Avg. Vol
2,584,693
52-wk High
3.53kr
52-wk Low
1.77kr

BINV.ST

Chart for BINV.ST

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for BINV.ST.

Overall

Beta: 0.60
Market Cap(Mil.): kr889.71
Shares Outstanding(Mil.): 304.70
Dividend: --
Yield (%): --

Financials

  BINV.ST Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -0.22 -- --
ROI: -48.16 -4.08 13.06
ROE: -48.16 4.84 14.19

BRIEF-Bioinvent Q4 net loss narrows

* Q4 profit/loss after tax: sek -7.3 (-21) million Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Feb 15 2017

BRIEF-Bioinvent cancels extraordinary general meeting

* Says Board intends instead to present the proposal for an incentive program for shareholder approval at the Annual General Meeting to be held on May 17, 2017. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jan 23 2017

BRIEF-Bioinvent's partner ThromboGenics initiates phase II study

* Bioinvent's collaboration partner ThromboGenics initiates phase II study with the drug candidate THR-317

Jan 10 2017

BRIEF-Bioinvent posts Q3 loss after tax of 29 mln SEK

* Q3 earnings after tax SEK -29 (-23) million. Further company coverage: (Reporting By Simon Johnson)

Oct 25 2016

BRIEF-Bioinvent says granted additional patent protection for BI-505

* Bioinvent expands patent approvals for its lead clinical immuno-oncology programme in multiple myeloma, bi-505

Sep 19 2016

BRIEF-BioInvent extends contract with existing customer, expects SEK 8 mln in revenue

* BioInvent extends manufacturing services contract with major global pharmaceutical client; expects to generate approximately SEK 8 million in revenue Further company coverage: (Reporting by Stockholm Newsroom)

Aug 29 2016

More From Around the Web

Earnings vs. Estimates